HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY 2108491

structure in first source

Also Known As:

LY-2108491; LY2108491

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - LY 2108491: 1
  - Sulfur Acids
    - Sulfonic Acids: 1605
      - Arylsulfonic Acids
        Arylsulfonates: 1
        LY 2108491: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - LY 2108491: 1

Experts

1.	Bramlett, Kelli S: 1 article (04/2006)
2.	Burris, Thomas P: 1 article (04/2006)
3.	Chandrasekhar, Srinivasan: 1 article (04/2006)
4.	Chin, William W: 1 article (04/2006)
5.	Chintalacharuvu, Subba R: 1 article (04/2006)
6.	Iturria, Stephen J: 1 article (04/2006)
7.	Kato, Shigeaki: 1 article (04/2006)
8.	Khalifa, Berket: 1 article (04/2006)
9.	Linebarger, Jared H: 1 article (04/2006)
10.	Lu, Jianfen: 1 article (04/2006)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 04/01/2006 - "Finally, these nonsecosteroidal VDRMs were less calcemic in vivo, and LY2108491 exhibited more than 270-fold improved therapeutic index over the naturally occurring VDR ligand 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] in an in vivo preclinical surrogate model of psoriasis."

Related Drugs and Biologics

1.	Ligands
2.	Calcitriol (Calcijex)